IL129178A0 - Induction of nerve generation - Google Patents

Induction of nerve generation

Info

Publication number
IL129178A0
IL129178A0 IL12917899A IL12917899A IL129178A0 IL 129178 A0 IL129178 A0 IL 129178A0 IL 12917899 A IL12917899 A IL 12917899A IL 12917899 A IL12917899 A IL 12917899A IL 129178 A0 IL129178 A0 IL 129178A0
Authority
IL
Israel
Prior art keywords
cgs
nerve
resulting
activities
treatment
Prior art date
Application number
IL12917899A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL12917899A priority Critical patent/IL129178A0/xx
Publication of IL129178A0 publication Critical patent/IL129178A0/xx
Priority to DE60018554T priority patent/DE60018554T2/de
Priority to BR0009296-7A priority patent/BR0009296A/pt
Priority to AU34517/00A priority patent/AU768911B2/en
Priority to JP2000607616A priority patent/JP2002540146A/ja
Priority to NZ514525A priority patent/NZ514525A/en
Priority to RU2001128743/15A priority patent/RU2247557C2/ru
Priority to PCT/IL2000/000185 priority patent/WO2000057865A2/en
Priority to US09/936,922 priority patent/US6914056B1/en
Priority to CN00806738A priority patent/CN1348375A/zh
Priority to MXPA01009650A priority patent/MXPA01009650A/es
Priority to IL14530000A priority patent/IL145300A0/xx
Priority to CA002368597A priority patent/CA2368597A1/en
Priority to EP00912877A priority patent/EP1162959B1/en
Priority to AT00912877T priority patent/ATE290385T1/de
Priority to HK02101620.4A priority patent/HK1042038A1/zh
Priority to KR1020017012158A priority patent/KR20010112364A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
IL12917899A 1999-03-25 1999-03-25 Induction of nerve generation IL129178A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation
KR1020017012158A KR20010112364A (ko) 1999-03-25 2000-03-24 신경 세포 분화를 촉진시키기 위한 환상 글리세로인산염및 그의 유사체를 포함하는 제약 조성물
RU2001128743/15A RU2247557C2 (ru) 1999-03-25 2000-03-24 Фармацевтические композиции, включающие циклические глицерофосфаты и их аналоги, для активации дифференцировки нервных клеток
US09/936,922 US6914056B1 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
AU34517/00A AU768911B2 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
JP2000607616A JP2002540146A (ja) 1999-03-25 2000-03-24 神経細胞分化を促進するための環状グリセロリン酸とその類似体を含む医薬組成物
NZ514525A NZ514525A (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
DE60018554T DE60018554T2 (de) 1999-03-25 2000-03-24 Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
PCT/IL2000/000185 WO2000057865A2 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
BR0009296-7A BR0009296A (pt) 1999-03-25 2000-03-24 Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto
CN00806738A CN1348375A (zh) 1999-03-25 2000-03-24 用于促进神经细胞分化的含有环状甘油磷酸酯及其类似物的药物组合物
MXPA01009650A MXPA01009650A (es) 1999-03-25 2000-03-24 Composiciones farmaceuticas que comprenden glicerofosfatos ciclicos y analogos de los mismos para estimular diferenciacion celular neuronal.
IL14530000A IL145300A0 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
CA002368597A CA2368597A1 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
EP00912877A EP1162959B1 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
AT00912877T ATE290385T1 (de) 1999-03-25 2000-03-24 Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
HK02101620.4A HK1042038A1 (zh) 1999-03-25 2000-03-24 用於促進神經細胞分化的含有環狀甘油磷酯及其類似物的藥物組合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation

Publications (1)

Publication Number Publication Date
IL129178A0 true IL129178A0 (en) 2000-02-17

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation

Country Status (16)

Country Link
US (1) US6914056B1 (enExample)
EP (1) EP1162959B1 (enExample)
JP (1) JP2002540146A (enExample)
KR (1) KR20010112364A (enExample)
CN (1) CN1348375A (enExample)
AT (1) ATE290385T1 (enExample)
AU (1) AU768911B2 (enExample)
BR (1) BR0009296A (enExample)
CA (1) CA2368597A1 (enExample)
DE (1) DE60018554T2 (enExample)
HK (1) HK1042038A1 (enExample)
IL (1) IL129178A0 (enExample)
MX (1) MXPA01009650A (enExample)
NZ (1) NZ514525A (enExample)
RU (1) RU2247557C2 (enExample)
WO (1) WO2000057865A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253918T1 (de) 1999-12-08 2003-11-15 Centre Nat Rech Scient Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
EP1511483A4 (en) * 2002-03-27 2009-03-18 Smithkline Beecham Corp PROCESSING METHODS USING LXR MODULATORS
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
US8101552B2 (en) * 2005-03-14 2012-01-24 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
NZ571975A (en) * 2006-04-26 2011-04-29 Toyama Chemical Co Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising benzothiopene alkyl ether derivative or salt thereof
EP2098237B1 (en) * 2006-12-28 2012-08-29 Ochanomizu University Analgesic agent comprising cyclic phosphatidic acid derivative
WO2010080969A1 (en) * 2009-01-09 2010-07-15 Sigma-Aldrich Co. Process for the synthesis of beta glycerol phosphate
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
JP6007264B2 (ja) 2013-01-28 2016-10-12 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
CA3007063A1 (en) * 2015-12-08 2017-06-15 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center １−ｏ−アシルグリセロール２，３−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素ｃの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) * 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Also Published As

Publication number Publication date
EP1162959B1 (en) 2005-03-09
CN1348375A (zh) 2002-05-08
US6914056B1 (en) 2005-07-05
DE60018554T2 (de) 2006-04-13
WO2000057865A3 (en) 2001-06-28
RU2247557C2 (ru) 2005-03-10
AU768911B2 (en) 2004-01-08
JP2002540146A (ja) 2002-11-26
NZ514525A (en) 2003-10-31
MXPA01009650A (es) 2002-07-02
BR0009296A (pt) 2001-12-18
WO2000057865A9 (en) 2001-11-15
EP1162959A2 (en) 2001-12-19
KR20010112364A (ko) 2001-12-20
AU3451700A (en) 2000-10-16
HK1042038A1 (zh) 2002-08-02
WO2000057865A2 (en) 2000-10-05
ATE290385T1 (de) 2005-03-15
DE60018554D1 (de) 2005-04-14
CA2368597A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
IL129178A0 (en) Induction of nerve generation
LTIP919A (en) Drugs and process for preparing thereof
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
PL398445A1 (pl) Kompozycje farmaceutyczne zawierające dekstrometorfan i chininę do leczenia zaburzeń neurologicznych
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
ATE229806T1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
AU2339792A (en) Treatment of respiratory disorders by nerve stimulation
ZA951292B (en) 4-amino derivatives of mycophenolic acid
EP1014881A4 (en) TREATMENT OF NEURODEGENERATIVE CONDITIONS BY INFUSION OF NERVOUS GROWTH FACTORS IN THE BRAIN
AU4331400A (en) Neurotrophic substituted pyrimidines
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
EP0616032A3 (en) Preventive or therapeutic agents against Alzheimer's disease, a screening method and the human tau kinase protein.
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
DE69636934D1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
AP9901473A0 (en) Use of benzopyranols to treat neurological disorders.
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
TW427986B (en) 4-amino 6-substituted mycophenolic acid and derivatives
BR0314541A (pt) Tratamento de demência e doença de parkinson
EP0457671A3 (en) Dipyridamide for the treatment of diseases of the central or peripheral nervous system
WO2005009359A3 (en) Agents, compositions and methods for enhancing neurological function
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's